IMMP

Immutep Limited (NASDAQ:IMMP) is an Australian biotechnology company founded in 1987 and originally known as Prima BioMed Ltd before rebranding in November 2017. The company is headquartered in Sydney, Australia, and has been publicly traded since its IPO in April 2012. Immutep focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases, with its lead drug candidate currently in Phase IIb clinical trials for metastatic breast cancer treatment.